Director Michael Goettler exits Bausch Health (NYSE: BHC) board
Rhea-AI Filing Summary
Bausch Health Companies Inc. announced that director Michael Goettler has resigned from its Board of Directors, effective June 30, 2026. He is leaving in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC.
The company states that Mr. Goettler’s resignation was not due to any disagreement regarding its operations, policies or practices. A press release dated July 1, 2026, describing the resignation is furnished as Exhibit 99.1. Bausch Health describes itself as a global diversified pharmaceutical company with products across multiple therapeutic areas and a controlling interest in Bausch + Lomb Corporation.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Terms
Board of Directors, Regulation FD Disclosure, Inline XBRL
3 terms
Board of Directors financial
"today announced that Michael Goettler has resigned from its Board of Directors, effective June 30, 2026"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
Regulation FD Disclosure regulatory
"Item 7.01 Regulation FD Disclosure A copy of the press release, dated July 1, 2026"
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
Inline XBRL technical
"104 | Cover Page Interactive Data File (formatted as Inline XBRL)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
Why did Michael Goettler resign from Bausch Health’s (BHC) Board of Directors?
Michael Goettler resigned from Bausch Health’s Board to become President and Chief Executive Officer of Knoa Pharma LLC. His departure is described as related to this new role rather than any issues with Bausch Health.
When is Michael Goettler’s resignation from the Bausch Health (BHC) board effective?
Michael Goettler’s resignation from Bausch Health’s Board of Directors is effective June 30, 2026. The company announced the change in a July 1, 2026 press release furnished as an exhibit to the report.
Did Michael Goettler have any disagreements with Bausch Health (BHC) leading to his resignation?
The company states that Michael Goettler’s resignation was not the result of any disagreement regarding Bausch Health’s operations, policies or practices. This language is intended to signal a routine change rather than a conflict-driven departure.
What document did Bausch Health (BHC) provide about Michael Goettler’s resignation?
Bausch Health furnished a press release dated July 1, 2026 as Exhibit 99.1 describing Michael Goettler’s resignation. The information is furnished under Regulation FD and is not deemed filed for liability purposes under Section 18.
What type of company is Bausch Health (BHC) according to this disclosure?
Bausch Health describes itself as a global, diversified pharmaceutical company. It develops, manufactures and markets products across gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health via its controlling interest in Bausch + Lomb.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| , | |||||||||||||||||
| (State or other jurisdiction of incorporation) | (Commission file number) | (IRS Employer Identification No.) | |||||||||||||||
(Address of Principal Executive Offices) (Zip Code)
(514 ) 744-6792
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | |||||||||
| Toronto Stock Exchange | |||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On June 26, 2026, Mr. Michael Goettler notified Bausch Health Companies Inc. (the “Company”) of his decision to resign from the Board of Directors (the “Board”), effective June 30, 2026, in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC.
Mr. Goettler’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Item 7.01 Regulation FD Disclosure
A copy of the press release, dated July 1, 2026, announcing Mr. Goettler’s resignation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in the preceding paragraph, as well as Exhibit 99.1 hereto, is being “furnished” pursuant to Item 7.01 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and is not incorporated by reference into any Company filing, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing and regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press release of the Company dated July 1, 2026 | |||||||
104 | Cover Page Interactive Data File (formatted as Inline XBRL) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BAUSCH HEALTH COMPANIES INC. | |||||
| By: | /s/ Seana Carson | ||||
| Name: | Seana Carson | ||||
| Title: | Executive Vice President, General Counsel | ||||
Date: July 1, 2026
Exhibit 99.1
| Investor Contact: | Media Contact: | ||||
Garen Sarafin | Katie Savastano | ||||
ir@bauschhealth.com | corporate.communications@bauschhealth.com | ||||
| (877) 281-6642 (toll free) | (908) 569-3692 | ||||
Michael Goettler Resigns from Bausch Health’s Board of Directors
LAVAL, Quebec, July 1, 2026 – Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Michael Goettler has resigned from its Board of Directors, effective June 30, 2026, in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC.
“We thank Michael for his valued service and wish him the best in his new role,” said John A. Paulson, Chairperson of the Bausch Health Board of Directors.
Mr. Goettler’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.
###